Greenspring Advisors LLC Makes New Investment in Johnson & Johnson $JNJ

Posted by Stanley Muller on Jun 4th, 2026

Greenspring Advisors LLC acquired a new position in shares of Johnson & Johnson (NYSE:JNJ – Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 7,353 shares of the company’s stock, valued at approximately $1,522,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Blueline Advisors LLC bought a new position in Johnson & Johnson during the fourth quarter worth $25,000. Cresta Advisors Ltd. bought a new stake in shares of Johnson & Johnson in the fourth quarter valued at about $26,000. Abich Financial Wealth Management LLC bought a new stake in shares of Johnson & Johnson in the third quarter valued at about $26,000. DecisionPoint Financial LLC boosted its position in shares of Johnson & Johnson by 104.2% in the fourth quarter. DecisionPoint Financial LLC now owns 147 shares of the company’s stock valued at $30,000 after acquiring an additional 75 shares during the period. Finally, Bay Harbor Wealth Management LLC boosted its position in shares of Johnson & Johnson by 49.0% in the fourth quarter. Bay Harbor Wealth Management LLC now owns 149 shares of the company’s stock valued at $31,000 after acquiring an additional 49 shares during the period. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Stock Up 0.3%

JNJ stock opened at $223.60 on Thursday. The company has a market cap of $538.25 billion, a PE ratio of 25.85, a price-to-earnings-growth ratio of 2.18 and a beta of 0.26. The business has a 50-day simple moving average of $232.25 and a 200 day simple moving average of $225.69. Johnson & Johnson has a 52 week low of $149.04 and a 52 week high of $251.71. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.46.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its quarterly earnings results on Tuesday, April 14th. The company reported $2.70 EPS for the quarter, beating analysts’ consensus estimates of $2.68 by $0.02. The business had revenue of $24.06 billion during the quarter, compared to the consensus estimate of $23.60 billion. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.Johnson & Johnson’s revenue for the quarter was up 9.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. Sell-side analysts anticipate that Johnson & Johnson will post 11.57 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 9th. Investors of record on Tuesday, May 26th will be paid a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a yield of 2.4%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.30. The ex-dividend date of this dividend is Tuesday, May 26th. Johnson & Johnson’s payout ratio is presently 61.97%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on JNJ shares. Raymond James Financial boosted their target price on shares of Johnson & Johnson from $237.00 to $258.00 and gave the company an “outperform” rating in a research report on Wednesday, April 15th. Leerink Partners raised shares of Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $265.00 target price for the company in a research report on Wednesday, May 13th. Bank of America boosted their target price on shares of Johnson & Johnson from $253.00 to $254.00 and gave the company a “neutral” rating in a research report on Wednesday, April 15th. Argus boosted their target price on shares of Johnson & Johnson from $240.00 to $275.00 and gave the company a “buy” rating in a research report on Thursday, April 16th. Finally, Citigroup boosted their target price on shares of Johnson & Johnson from $274.00 to $285.00 and gave the company a “buy” rating in a research report on Tuesday, April 7th. Twenty analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $253.04.

Get Our Latest Research Report on Johnson & Johnson

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

Positive Sentiment: Johnson & Johnson reported encouraging Phase 2 results for nipocalimab in lupus, meeting the primary endpoint and showing sustained disease activity reduction through 52 weeks. Article Title
Positive Sentiment: New Sjögren’s disease data further reinforced nipocalimab’s ability to reduce autoantibodies and showed stronger response rates in patients with higher disease burden. Article Title
Neutral Sentiment: Johnson & Johnson is drawing extra investor attention, likely reflecting renewed focus on the stock after the recent pipeline updates and broader interest in defensive healthcare names. Article Title
Neutral Sentiment: Commentary on Johnson & Johnson as a potential high-growth dividend stock may be supporting the company’s income-investor appeal, but it does not appear to reflect a new operating development. Article Title
Neutral Sentiment: Scotiabank reiterated a Buy rating on Johnson & Johnson, which can help reinforce confidence in the stock among investors. Article Title

About Johnson & Johnson

(Free Report)

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.